ASSERTION FOR MONTELUKAST IN THE COVID-19 PANDEMICS?
ANDRA IULIA SUCEVEANU 1#, LAURA MAZILU 1, ADRIAN PAUL SUCEVEANU 1, IRINEL PAREPA 1, ION-BOGDAN DUMITRESCU 2*, CRISTINA MANUELA DRĂGOI 2, ALINA CRENGUȚA NICOLAE 2, FLORIN BOTEA 3, FELIX VOINEA 1#, GEORGE TRAIAN ALEXANDRU BURCEA-DRAGOMIROIU 2
1.Faculty of Medicine, “Ovidius” University of Constanța, Romania
2 .“Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
3 .Liver Transplant and General Surgery Centre, Fundeni Intitute, 022338, Bucharest, Romania
Download Full Article PDF
The ongoing pandemic coronavirus disease (COVID-19) is an infection caused by a newly discovered severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). The treatment of COVID-19 patients represents a continuous challenge, no vaccine or specific antiviral therapy is yet available. International guidelines recommend the medical management based only on the first line physicians' short expertise, off-label approaches being admitted worldwide to limit and to decrease the infection devastating impacts on humans’ health. A marketed drug used for asthma, known generically as montelukast, gives light in the attempt of clinicians during their efforts to combat SARS-CoV2 spreading. Even not yet approved by FDA or EMA for COVID-19 infection indication, many clinicians are raising-up the idea of turning attention and attempts to off-label medical options like montelukast use, considering this drug an alternative or additive therapeutic approach for prevention and treating pulmonary distress.
